CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
aprepitant +2 moredrug
Likely dose
aprepitant 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02210195
NCT02210195Phase 2Completed
CompareCT.gov

Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence

The Scripps Research Institute·interventional·Posted Aug 6, 2014·Updated Aug 2, 2017

In Brief

A Phase 2 clinical trial evaluating aprepitant, Placebo, and 1 other intervention for Cannabis Dependence and 3 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The primary aim of the supplemental study is to provide POC testing of aprepitant as a treatment for comorbid alcohol and cannabis dependence. The data analysis plan specified in the parent grant will likewise be applied to the supplemental project to test for effects of aprepitant vs placebo on measures of alcohol and cannabis use and protracted withdrawal. The primary hypothesis is that subjects treated with aprepitant will have significantly less alcohol and marijuana use than subjects treated with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Dependence, Alcohol Dependence, Cannabis Use Disorder, Alcohol Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 6, 2014
Enrollment StartSep 4, 2014
Primary CompletionDec 19, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.9 years ago

Interventions

aprepitantdrug

125 mg daily for 8 weeks.

Placebodrug

Placebo daily for 8 weeks.

Manual-guided behavioral counselingbehavioral

Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.